A crystalline sponge reveals structures of large beyond rule of 5 molecules

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-08T21:08:13.206Z • Permanent link

Researchers at the University of California, Los Angeles (UCLA), have made a groundbreaking discovery in the field of drug discovery, revealing the structures of large molecules beyond the traditional "rule of 5." This breakthrough has far-reaching implications for the pharmaceutical industry, which has long relied on this rule to identify chemical properties associated with good absorption of orally administered drugs.

Led by Dr. Jennifer Doudna, a renowned biochemist and professor at UCLA, the research team used advanced techniques to crystallize a complex molecule known as PAM3CSK5, a compound that has been shown to have potent antimicrobial properties. By solving the crystal structure of PAM3CSK5, the researchers were able to gain valuable insights into its molecular interactions and identify potential targets for drug development.

The discovery was made possible by the development of a novel crystallization technique, which allowed the researchers to grow high-quality crystals of PAM3CSK5. This technique, known as "single-crystal protein X-ray crystallography," involves the use of advanced computational methods and sophisticated instrumentation to create crystals that are identical in structure and composition. The UCLA team's achievement has significant implications for the field of drug discovery, as it paves the way for the development of new therapies that can target complex molecules like PAM3CSK5.

The breakthrough at UCLA has significant implications for the AI and tech ecosystem, particularly in the areas of data analysis and computational modeling. The development of new techniques for crystallizing complex molecules like PAM3CSK5 has the potential to revolutionize the field of drug discovery, enabling researchers to design and develop new therapies that can target a wide range of diseases.

Companies such as Pfizer and Johnson & Johnson, which have significant investments in AI and data analytics, are likely to be impacted by this breakthrough. These companies have already begun to leverage AI and machine learning to accelerate the discovery and development of new therapies, and the UCLA discovery is likely to further accelerate this trend. Researchers in the field of machine learning are also likely to be interested in the data analysis techniques used in the UCLA study, as these techniques have the potential to improve the accuracy and efficiency of machine learning models.

The breakthrough at UCLA is part of a larger pattern of innovation in the field of drug discovery, which has seen significant advances in recent years. The development of new techniques such as CRISPR-Cas9 gene editing has enabled researchers to target specific genes and pathways, leading to the development of new therapies for a range of diseases. Similarly, advances in AI and data analytics have enabled researchers to analyze large datasets and identify patterns that may not have been apparent through traditional methods.